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β-Diketonate versus β-Ketoiminate: The Importance of a
Ferrocenyl Moiety in Improving the Anticancer Potency
Matthew Allison,[a] Daniel Wilson,[a] Christopher M. Pask,[a] Patrick C. McGowan,*[a] and
Rianne M. Lord*[b, c]
Herein we present a library of fully characterized β-diketonate
and β-ketoiminate compounds that are functionalized with a
ferrocenyl moiety. Their cytotoxic potential has been deter-
mined by screening against human breast adenocarcinomas
(MCF-7 and MDA-MB-231), human colorectal carcinoma p53
wild type (HCT116 p53+ /+) and normal human prostate (PNT2)
cell lines. The ferrocenyl β-diketonate compounds are more
than 18 times more cytotoxic than the ferrocenyl β-ketoiminate
analogues. Against MCF-7, compounds functionalized at the
meta position are up to nine times more cytotoxic than when
functionalized at the para position. The ferrocenyl β-diketonate
compounds have increased selectivity towards MCF-7 and
MDA-MB-231, with several complexes having selectivity index
(SI) values that are more than nine times (MCF-7) and more
than six times (MDA-MB-231) that of carboplatin. The stability
of these compounds in dimethyl sulfoxide (DMSO) and dimeth-
ylformamide (DMF) has been assessed by NMR spectroscopy
and mass spectrometry studies, and the compounds show no
oxidation of the iron center from FeII to FeIII. Cytotoxicity
screening was performed in both DMSO and DMF, with no
significant differences observedin their potency.
Cisplatin, cis-[Pt(NH3)2Cl2],
[1] is the best-known metal-based
compound widely used in the clinic for the treatment of
cancer.[2,3] Since its success, a variety of platinum-based
therapeutics have been designed and tested,[4,5] however,
alternatives are being developed due to tumors developing
platinum resistance, which have rendered the platinum-based
drugs ineffective. Due to the inability of the platinum com-
pounds to target the cancerous cells over normal cells, high
levels of toxicity are observed, leading to severe side-effects
such as nephrotoxicity.[6] There has been a surge in research
towards different metal-based therapeutics,[7–11] including orga-
nometallic compounds. Ferrocenyl compounds derived from
tamoxifen, are known as ferrocifens, and are amongst the
earliest organometallic selective estrogen receptor modulators
(SERM).[12,13] Ferrocenyl hydroxytamoxifen (Fc-OH-Tam, Fig-
ure 1A)[14] is one of the leading compounds of this class, and
possesses anti-proliferation against both hormone-dependent
(MCF-7) and hormone-independent (MDA-MB-231) breast can-
cer cells. Additionally, Fc-OH-Tam, has been shown to signifi-
cantly inhibit in vivo growth of MDA-MB-231 xenografted
tumors in mice when formulated in lipid nanocapsules
(LNCs).[15,16] The dual effect of targeting both MCF-7 and MDA-
MB-231 is very significant, since the organic compound
hydroxytamoxifen (OH-Tam) shows activity against MCF-7 only.
This highlights the importance the ferrocenyl moiety on the
increased activity against breast cancers.[17]
Although the mechanism of action is still not fully under-
stood, it was found that such Fc-OH-Tam compounds can
generate hydroxyl radicals in physiological solutions, and this
Fenton-type reaction is thought to lead to DNA damage by
radicals.[17,18] Since this discovery, there have been many
ferrocenyl derived compounds which have been synthesized
and screened for their cellular activities.[19–22] It was also shown
that Fc-OH-Tam can induce strong senescence in MDA-MB-231
cells and exhibits low apoptosis.[23] Electron transfer processes
between the ferrocenyl and ferrocenium states are fast and
reversible, and the ferrocenyl moiety will exist as a mixture of
the neutral ferrocenyl and cationic radical ferrocenium
species.[24–26] It was therefore suggested that such compounds
can be administered in either the reduced ferrocenyl or
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Figure 1. Chemical structures of A) ferrocenyl hydroxytamoxifen[14] and B)
ferrocenyl β-diketonates.[30]
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oxidized ferrocenium state, providing the formal reduction
potential of the ferrocenyl group is low enough to allow
ferrocenyl oxidation inside a cell. Many researchers have shown
that this oxidation from FeII to FeIII can cause the compounds to
undergo chemical oxidation to give quinone methides (QM)[27,28]
which were able to strongly inhibit in vitro thioredoxin
reductase (TrxR).[28,29]
Swarts and co-workers developed and screened ferrocenyl
β-diketonates, and also provided evidence that halides had a
significant effect on the compound’s cytotoxicity (Figure 1B).[30]
The compound functionalized with a CF3 moiety exhibited low
μM activity against colorectal adenocarcinoma (CoLo 320DM),
and was more cytotoxic than cisplatin. We have previously
synthesized a range of β-diketonate and β-ketoiminate ligands,
which we have used for complexation reactions with metals
such as Ti, Ru and Ir.[31–33] However, the ligands exhibit no
toxicity, with IC50 values >100 μM. Herein, we have functional-
ized these ligands with ferrocenyl and extended the library
published by Swarts et al. (Figure 1B). We report an increase in
cytotoxicity against human carcinomas, highlighting the ferro-
cenyl β-diketonate ligands to be more cytotoxic than the
ferrocenyl β-ketoiminate analogues. The stability of these
compounds has been assessed by NMR and mass spectroscopy
in DMSO and DMF over 4 days, showing no oxidation of the
iron centers, but the possibility of new species in solution.
Additionally, the compounds were screened against a colorectal
carcinoma cell line, HCT116 p53+ /+ , after being dissolved in
DMF. The results are similar to those obtained in DMSO, unlike
the clinical platinum compounds, where carboplatin and
oxaliplatin become less cytotoxic in DMF.
A simple acid-catalyzed Friedel-Crafts acylation was used to
synthesize acetyl ferrocene, which was purified by column
chromatography, followed by a Claisen condensation with a
functionalized acetophenone (1 eq.). Compound 1 was synthe-
sized by refluxing acetyl ferrocene (1 eq.), sodium ethoxide
(2 eq.) and ethyl acetate for 3 hours. After an acid work up and
recrystallization from hexane, red crystals were obtained in an
81% yield (Scheme 1A). Complexes 2–7 were synthesized by
refluxing acetyl ferrocene (1 eq.), sodium ethoxide (1 eq.) and a
functionalized ethyl benzoate (1 eq.) in diethyl ether for 3 hours
(Scheme 1A). These compounds were purified by column
chromatography and obtained in yields of 63–93%. Com-
pounds 8–14 were synthesized by addition of compound 1
(1 eq.), to a functionalized aniline (excess) and a catalytic
amount of concentrated hydrochloric acid. The reaction mixture
was stirred at room temperature for 3 days, and after removal
of the solvent and purification, the compounds were obtained
in 34–68% yields (Scheme 1B). All compounds were fully
characterized by 1H NMR and 13C{1H} NMR spectroscopy,
elemental analysis, high resolution mass spectrometry and
single crystal X-ray diffraction where possible.
Crystal structures of compounds 1–13 are reported herein,
and the crystal structure of compound 14 has previously been
published.[34] Red/orange single crystals suitable for X-ray
crystallographic analysis were obtained for compounds 1–7, by
slow evaporation of an acetonitrile solution (Figure 2). Com-
pound 1 has previously been published, however, this is the
first time a crystal structure has been obtained. The compounds
all crystallized in either an orthorhombic or monoclinic cell, and
structures were solved in space groups P212121 (1), P21/n (2, 6,
7), C2/c (3, 4) or P21/c (5). The cyclopentadienyl (Cp) substituents
of the ferrocenyl adopt an eclipsed conformation in all cases,
with the exception of compound 7, which has a disordered
staggered Cp rings. The eclipsed arrangement has been
postulated to be the energetically preferred conformer.[35,36] The
β-diketonate section of the compounds are all planar, withScheme 1. Synthesis of A) ferrocenyl β-diketonate compounds 1–7 and B)ferrocenyl β-ketoiminate compounds 8–14.
Figure 2. Molecular structures of ferrocenyl β-diketonate compounds 1–7. Displacement ellipsoids are at the 50% probability level, and hydrogen atoms and
disordered atoms are omitted for clarity.
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O1  C11  C12  O2 angles of 119–122° (Table S3) and carbonyl
bond lengths of 1.2–1.3 Å (Table 1). Short intramolecular hydro-
gen bonding interactions are observed between O(1)-H···O(2), at
a distance of 2.4–2.5 Å (D···A) in all cases, which is characteristic
for such acetylacetone molecules in their enol formation.
Red/orange singles crystals suitable for X-ray crystallo-
graphic analysis were obtained for compounds 8–13, by slow
cooling from hot ethanol then storing at   20 °C or by slow
evaporation from acetone (Figure 3). The compounds crystal-
lized in either a monoclinic or orthorhombic cell, and structures
were solved in the space group P21/c (8, 10, 11 and 13), P21/n
(12), or Pca21 (9). In the case of the β-ketoiminate compounds,
the Cp moiety adopts an eclipsed conformation in all cases. As
with the previous compounds, compound 8–13 have short
intramolecular hydrogen bonding, with O1···H  N1 distances of
2.5–2.6 Å (D···A). All crystallographic data are stated in
Table S1a–b (1–7) and Table S2a–b (8–13).
The ferrocenyl β-diketonate compounds are distinguishable
by the presence of the methine singlet at ~5.5–6.5 ppm, and in
some solvents the appearance of the OH resonance at
~16.0 ppm. Upon synthesis of the ferrocenyl β-ketoiminate
compounds, the methine resonances undergo a minor shift and
the disappearance of the OH resonance, with the appearance of
a new aniline NH resonance at 11–13 ppm verifying the
successful synthesis. NMR samples were first prepared in CDCl3,
however, broad resonances were observed (Figure 4, blue). This
was attributed partly to the fluctuating nature of the ligands, as
they can undergo tautomerisation between the cyclic enol and
diketo forms.[37–39] The use of more polar solvents, that is [D3]
acetonitrile, stabilized the enol system through hydrogen
bonding interactions, producing sharp resonances in the NMR
spectra (Figure 3, green).
To address the stability of these compounds prior to cell
screening, 1H NMR spectroscopy was used to monitor any
changes in the compounds, and the unfunctionalized ferrocenyl
β-diketonate compound 1 and unfunctionalized ferrocenyl β-
ketoiminate compound 8 were used in this study. The
compounds (5 mg) were dissolved in [D6]DMSO and an initial
spectrum taken, and then recorded at varying time intervals
between initial and 4 days. Selected time intervals are shown
for compounds 1 and 8, in Figures 5 and 6, respectively. Both of
the compounds show the appearance of new resonances which
are also similar to those observed in the 4 day NMR spectra of
Table 1. Selected bond lengths for ferrocenyl β-diketonate compounds 1–
7 and ferrocenyl β-ketoiminate compounds 8–13.
Bond lengths [Å]
Cmpd C11  O1 C11  C12 C12  C13 C13  O2 or
C13  N1
1 1.284(6) 1.412(8) 1.371(8) 1.320(7)
2 1.266(3) 1.449(4) 1.366(4) 1.331(3)
3 1.260(5) 1.441(5) 1.363(5) 1.329(5)
4 1.262(2) 1.437(3) 1.358(3) 1.334(2)
5 1.302(2) 1.397(3) 1.400(3) 1.294(2)
6 1.274(7) 1.433(8) 1.355(8) 1.332(7)
7 1.276(9) 1.425(10) 1.359(11) 1.320(10)
8 1.2560(18) 1.433(2) 1.373(2) 1.3561(10
9 1.25(5)/
1.25(4)
1.29(5)/
1.56(5)
1.35(6)/ 1.30(6) 1.34(6)/
1.32(5)
10 1.258(2) 1.429(3) 1.372(3) 1.346(3)
11 1.260(3) 1.425(3) 1.378(4) 1.341(3)
12 1.24(5)/
1.20(4)
1.44(5)/
1.47(6)
1.37(7)/
1.35(6)
1.29(6)/
1.36(5)
13 1.267(5) 1.438(5) 1.374(6) 1.358(5)
Figure 3. Molecular structures of ferrocenyl β-diketonate compounds 8–13. Displacement ellipsoids are at the 50% probability level, and hydrogen atoms and
disordered atoms are omitted for clarity.
Figure 4. 1H NMR spectra (400 MHz, 298 K) of unfunctionalized ferrocenyl β-
diketonate compound 1 in CDCl3 (blue), [D3]acetonitrile (green) and [D6]
acetone (red ).
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acetyl ferrocene (Figures S1 and S2, respectively), showing there
is likely some rearrangement of the compounds in solution, but
no decomposition to acetyl ferrocene or ferrocene. Although
the solutions turn darker in color over time (Figures S5 and S6),
the NMR spectra do not broaden and there is no evidence of
paramagnetic resonances, indicating no oxidation from FeII to
FeIII.
The stability of compounds 1 and 8 were also assess by
dissolving 5 mg in [D7]DMF and
1H NMR spectra recorded at the
same time intervals as previously discussed. Although DMF
solutions of compound 1 appear to darken over 2 hours
(Figure S5), the spectra showed no significant changes until day
4. In comparison, compound 8 exhibited significant changes in
the aromatic region (7.0–7.5 ppm) after only 30 mins, unlike the
studies in DMSO, which shows the compound changing slowly
over time (Figures 6 and S4). These changes were surprising, as
compound 8 did not experience darkening of the solution
when dissolved in DMF for 2 hours (Figure S6). As with the
DMSO results, the NMR spectra in DMF do not broaden and
there is again no evidence of paramagnetic resonances,
indicating no oxidation from FeII to FeIII. In attempts to establish
the structures in solution, mass spectrometry was performed
after samples were dissolved in DMSO or DMF over a period of
4 days. Although there is evidence of each compound in
solution over time, there are multiple new mass peaks which
could not be assigned to known species, and we were unable
to elucidate the structures or rearrangement products of these
compounds in solution (Table S4).
The range of compounds were screened for their cytotox-
icity against human breast adenocarcinomas MCF-7 and MDA-
MB-231, and human colorectal carcinoma p53 wild type,
HCT116 p53+ /+ cell lines. Stock solutions in DMSO (100 mM)
were made fresh on each day of testing, and were immediately
(<5 mins) plated with the cell lines for 96 h (DMSO <0.1% v/v)
before performing an MTT assay. The clinical drugs cisplatin
(CDDP), oxaliplatin (OXA) and carboplatin (CARB) were screened
for comparison. The results are shown in Table 2 and Figure 7,
and across all of the cell lines tested, there is a general trend
whereby the ferrocenyl β-diketonate compounds 1–7 are more
cytotoxic than the analogous ferrocenyl β-ketoiminate com-
pounds 8–14. The most significant differences are observed
against the triple negative breast adenocarcinoma, MDA-MD-
231, where the ferrocenyl β-diketonate compounds are >18
times more cytotoxic than the ferrocenyl β-ketoiminate com-
pounds (6 cf. 13, see Figure S7). In comparison, this is contrary
to our previously investigated RuII and IrIII complexes, in which
the β-ketoiminate complexes were more cytotoxic than those
with a β-diketonate ligand, where the latter were generally
nontoxic.[31–33]
The unfunctionalized ferrocenyl β-diketonate compound 1
is moderately cytotoxic towards all cell lines, and generally the
toxicity increases when the compound is functionalized with a
halide substituent. Compounds 2–4 have a halide in the meta
position of the arene ring, and the 3’-F (2) position has
increased cytotoxicity when compared to 3’-Cl (3) and 3’-Br (4),
following the order 2>3>4. When using the same substituents
in the para position (5–7), the activity is generally reversed and
the 4’-Br compound 7 is more cytotoxic than the 4’-F (5) and 4’-
Figure 5. 1H NMR spectra (298 K, 400 MHz) of ferrocenyl β-diketonate
compound 1 in DMSO at selected time intervals from initial to 4 days.
Figure 6. 1H NMR spectra (298 K, 400 MHz) of ferrocenyl β-ketoiminate
compound 8 in DMSO at selected time intervals from initial to 4 days.
Figure 7. Bar-chart of IC50 values against MCF7, MDA-MB-231, HCT116
p53+ /+ and PNT2 for cisplatin (CDDP), carboplatin (CARB), oxaliplatin (OXA),
ferrocenyl β-ketoiminate compounds 1–7, and ferrocenyl β-ketoiminate
compounds 8–14.
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Cl (6), following the order 7>6>5. This highlights the
importance of the position of the halide substituent on the
compound’s in vitro activity, and the meta substituted com-
pounds are up to 9 times more cytotoxic than the para
substituted compounds against MCF-7 (2 cf. 5). The ferrocenyl
β-diketonate compounds have an increased sensitivity towards
the MDA-MD-231 cell line, with compounds 2, 3, 5 and 7 having
IC50 values ranging from 5.4–5.8 μM . They have comparable
activity to CDDP (p>0.05) and are >5 times more cytotoxic
than CARB (p<0.05).
The unfunctionalized ferrocenyl β-ketoiminate compound 8
is nontoxic against all cell lines (IC50>100 μM), and is up to 3.5
times less cytotoxic than the analogues β-diketonate com-
pound 1 (HCT116 p53+ /+). There are no general trends
observed when these compounds are functionalized in the
meta position of the aniline ring, although the 3’-Br compound
11 has the lowest toxicity. When comparing the halide
functionalization in the para position, unlike the ferrocenyl β-
diketonate compounds 6 and 7, the 4’-Cl (13) and 4’-Br (14) β-
ketoiminate compounds are nontoxic against all cell lines
(IC50>100 μM) and are up to 18.5 time less toxic than their β-
diketonate analogues (6 cf. 13, see Figure S5). The 4’-F
compound 12 is the only para substituted β-ketoiminate
compound to show moderate cytotoxicity, with values ranging
between 43–55 μM, and is up to 2.3 times more cytotoxic than
compounds 13 and 14 (MDA-MB-231, p<0.05).
In order to assess the compounds’ selectivity towards
cancerous cells, the compounds and clinical drugs were
screened against normal prostate epithelium cells, PNT2
(Table 2 and Figure 8). Generally, the IC50 values show the
ferrocenyl β-diketonate compounds 1–7 are between 2.2 (2 cf.
9) and 10.6 times (4 cf. 11) more potent towards normal cells,
than the ferrocenyl β-ketoiminate compounds 8–14. The IC50
values of compounds against PNT2 were divided by the IC50
values against either of the cancerous cell lines, to give a
selectivity index (SI) value. The SI values are shown in
parentheses of Table 2 and displayed as a bar-chart in Figure 9.
SI values >1 indicate a selectivity for the cancerous cell line,
and highlight the potential to overcome issues of toxicity
towards healthy cells. The clinical compound OXA has no
selectivity for cancerous cells, with all SI values <1. However,
CDDP shows the highest selectivity, with all SI values between
2.8–5.7, whilst CARB is only selective towards HCT116 p53+ /+
(SI=4.5).
The ferrocenyl compounds 1–14 generally do not have a
selectivity towards MCF-7, except for compounds 1 and 2,
which have SI values of 1.9. The compounds have a higher
selectivity towards MDA-MB-231 and HCT116 p53+ /+ , with SI
values ranging from 0.6–3.7 and 0.9–3.6, respectively. The
ferrocenyl β-diketonate compounds 1–7 are generally more
Table 2. IC50 values [μM]�SD after 96 h incubation with MCF-7, MDA-MD-231, HCT116 p53
+ /+ , and PNT2. All values are averages of duplicate of triplicate
repeats. The values in parentheses are the selectivity index (SI) values, when compared to the normal cell lines PNT2.
Compound IC50 values [μM]�SD
MCF-7 MDA-MB-231 HCT116 p53+ /+
DMSO
HCT116 p53+ /+
DMF
PNT2
CDDP 1.5�0.2 (5.7) 3.07�0.02 (2.8) 1.5�0.1 (5.7) 2.3�0.1 8.5�0.4
CARB >100 (<0.27[a]) 33�2 (0.8) 6.0�0.2 (4.5) 45�2 27�2
OXA 2.6�0.2 (0.5) 2.6�0.4 (0.5) 0.445�0.002 (2.9) 1.6�0.1 1.3�0.2
1 54�4 (1.9) 47�3 (2.1) 28�1 (3.6) 32�1 >100
2 11�1 (1.9) 5.7�0.5 (3.7) 11.3�0.7 (1.9) 9.3�0.4 21�4
3 13�1 (0.7) 5.8�0.9 (1.6) 10.1�0.5 (0.9) 5.8�0.2 9.0�0.5
4 77�5 (0.1) 8.1�0.4 (1.2) 6.0�0.2 (1.6) 4.45�0.09 9.4�0.1
5 >100 (<0.2[a]) 18.6�0.5 (1.1) 11.2�0.9 (1.9) 10.7�0.6 21�2
6 46�3 (0.2) 5.4�0.6 (2.1) 10.3�0.6 (1.1) 4.8�0.6 11.1�0.4
7 31�3 (0.3) 5.6�0.2 (1.7) 6.7�0.4 (1.4) 5.6�0.5 9.4�0.6
8 >100 (n.d.) >100 (n.d.) >100 (n.d.) 59�2 >100
9 86�3 (0.5) 80�2 (0.6) 43�2 (1.1) 52�2 46�2
10 90�5 (1.0) 77�5 (1.1) 53.1�0.9 (1.7) 43�2 88�3
11 >100 (n.d.) >100 (n.d.) 47�2 (>2.1[a]) 41�2 >100
12 55�4 (1.3) 43�3 (1.7) 51.6�0.7 (1.4) 56�2 72�2
13 >100 (n.d.) >100 (n.d.) >100 (n.d.) 86�2 >100
14 >100 (<1.0[a]) >100 (<1.0[a]) >100 (<1.0[a]) 84�2 99�1
[a] denotes the minimum SI value, as at least one of the IC50 values is >100 μM n.d. denotes the values which cannot be determined, as both of the IC50
values are >100 μM
Figure 8. SI values for CDDP, CARB, OXA, and compounds 1–14 when
comparing the IC50 values against cancerous and PNT2. SI>1 indicates
selectivity for the cancer cell lines, SI=1 indicates equitoxicity for cancerous
and normal cell lines, and SI <1 indicates selectivity for the PNT2.
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selective than the analogous ferrocenyl β-ketoiminate com-
pounds 8–14. In particular, compounds 1 and 2 have the
highest selectivity against all cell lines. On comparing com-
pounds 1 with 8 (R=H) and 2 with 9 (R=3’-F), compound 1 is
at least 3.6 times more selective than 8 (HCT116 p53+ /+), whilst
2 is at least 6.4 times more selective than 9 (MDA-MB-231).
The SI values were also calculated for compounds 1–14 in
comparison with CDDP, CARB and OXA. The results for CDDP
and OXA show no selectivity, and these clinical compounds
outperform our library or ferrocenyl compounds (Figures S8
and S9). However, compounds 1–14 are generally more
selective for breast cancer cell lines MCF-7 and MDA-MB-231,
when compared to CARB (Figure 9). On comparison of CARB
and compounds 2 and 3, these compounds have increased
selectivity against MCF-7, with SI values of 9.1 and 7.8,
respectively. Whilst compounds 2–7 are all more selective than
CARB against MDA-MB-231, with SI values up to 6.1 (6). As with
the other cytotoxicity results, the ferrocenyl β-diketonate
compounds 1–7 are generally more selective than ferrocenyl β-
ketoiminate compounds 8–14 when compared to CARB, with SI
values up to 18.5 times higher (6 cf. to 13 against MDA-MB-
231).
Due to the differences observed in the NMR spectroscopy of
the compounds in [D6]DMSO and [D7]DMF (Figures 4 and 5 and
S3–S6), and the previously reported cytotoxicity differences
observed when iridium compounds were screened in DMSO
and DMF,[40] the compounds 1–14 were screened against
HCT116 p53+ /+ after being dissolved in DMF. As with the DMSO
screening, 100 mM stock solutions of compounds 1–14 and the
clinical drugs (CDDP, OXA, CARB) were freshly prepared in DMF
and immediately (<5 mins) incubated with cell lines for 96 h
(DMF<0.1% v/v) before performing an MTT assay. The IC50
values for CDDP are comparable (p>0.05), however, the values
for OXA and CARB significantly decrease in DMF (Table 2 and
Figure 10), by 3.6 and 7.6-fold, respectively. On comparison of
the IC50 values of compounds 1–14 in DMSO and DMF, with the
exception of compound 8, where the IC50 value increases in
DMF (1.6-fold), all compounds have similar activities in both
DMSO and DMF, indicating that neither of these solvents has a
significant effect on the overall cytotoxicity. Yi and Bae high-
lighted the decrease in cytotoxicity of the clinical platinum
compounds against human ovarian carcinoma (A2780) when
changing solvents from DMSO to DMF.[40] Which is contradictory
to what was observed by Gasser and co-workers, where the
cytotoxicity of iridium compounds and CDDP against A2780
and HeLa generally increased in DMF.[40]
In conclusion, we report the synthesis of seven ferrocenyl β-
diketonate compounds (1–7) and seven ferrocenyl β-ketoimi-
nate compounds (8–14), including single crystal X-ray analysis
of thirteen new compounds. 1H NMR studies were used to
assess the compounds’ stabilities in [D6]DMSO and [D7]DMF,
and results indicate no oxidation of the metal center from FeII
to FeIII over a 4 day period, yet there is a possible rearrange-
ment of the compound in solution. Additional mass spectrom-
etry analysis was conducted to understand the possible
structure in DMSO and DMF over time, yet no conclusions could
be drawn to the species in solution. The library of compounds
were screened against human breast carcinoma (MCF-7, MDA-
MB-231), human colorectal adenocarcinoma, p53 wild type
(HCT116 p53+ /+) and normal human prostate cell line (PNT2)
cell lines. Generally, the ferrocenyl β-diketonate compounds
show a significant increase in cytotoxicity when compared to
the analogues ferrocenyl β-ketoiminate compounds. Several
compounds are more cytotoxic when compared to CARB,
particularly against MCF-7 (SI>9x) and MDA-MB-231 (SI>6x).
When comparing the results against normal prostate cells,
PNT2, the ferrocenyl β-diketonate compounds are less selective
than the clinical platinum drugs against MCF-7, however, they
exhibit greater selectivity towards MDA-MB-231 and HCT116
p53+ /+ . Additional chemosensitivity studies were conducted
after stock solutions were made in DMF. The results highlight
only small changes are observed in the compounds potency,
whereas the clinical platinum drugs (CDDP, CARB, OXA) in DMF
all show varying degrees of lower toxicity when screened
against HCT116 p53+ /+ .
Figure 9. SI values for compounds 1–14 when comparing the IC50 values
with CARB. SI >1 indicates selectivity for the ferrocenyl compounds, SI=1
indicates equitoxicity and SI <1 indicates selectivity for CARB.
Figure 10. Bar chart of IC50 values against HCT116 p53
+ /+ when compounds
were dissolved in either DMSO (purple) or DMF (grey)
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Experimental Section
The general experimental details, X-ray crystallography and cell
culture protocols can be found in the Supporting Information.
Synthesis of [C14H14FeO2] (1): Acetyl ferrocene (2.80 g, 12.3 mmol)
was dissolved in ethyl acetate (25 mL) and stirred before the
addition of sodium ethoxide (1.70 g, 25.0 mmol). The solution was
stirred at reflux for 3 h forming a yellow solid which was filtered
and washed with ethyl acetate. The yellow solid was then dissolved
in distilled water (150 mL) and acidified with 10% hydrochloric acid
until pH 5 which caused a red solid to precipitate. Recrystallization
from hexane gave red crystals (the resonances for enol are stated,
however, a small amount of the diketonate resonance form is
observed). Yield: 2.70 g, 81%; 1H NMR (500 MHz, CDCl3, δ): 5.63 (s,
1H, methine CH), 4.77 (br. t, 2H, 3J(1H-1H)=6.8 Hz, Cp-CH), 4.50 (d,
2H, 3J(1H-1H)=4.1 Hz, Cp-CH), 4.19 (s, 5H, Cp-C5H5), 2.00 (s, 3H, CH3);
13C{1H} NMR (125 MHz, CDCl3, δ): 192.5 (Q, CO), 186.4 (Q, CO), 98.2
(methine CH), 77.7 (Q, Cp), 73.1 (Cp-CH), 72.1 (Cp-CH), 70.3 (Cp-
C5H5), 70.1 (Cp-CH), 68.7 (Cp-CH), 24.2 (CH3); Analysis Calculated for
C14H14FeO2: C 62.25, H 5.22%, Found: C 62.28, H 5.10%; HRMS [ES
+]:
271.041 [MH+]
Synthesis of compounds 2–7: Acetyl ferrocene (1 eq.) was
dissolved in diethyl ether (20 mL) and with stirring sodium ethoxide
(1 eq.) and a functionalized benzoate (1 eq.) were added, and the
mixture refluxed for 24 h. The solid precipitate was isolated by
filtration, dissolved in distilled water (150 mL) and acidified with
10% hydrochloric acid until pH 5 which caused a red solid to
precipitate. The solid was filtered and dried overnight under
vacuum before purification.
[C19H15FFeO2] (2): The product was purified by column chromatog-
raphy, eluting with 83 :17 v/v hexane/ethyl acetate to give a red
solid. Yield: 2.00 g, 80%; 1H NMR (500 MHz, (CD3)2CO, δ): 7.77 (br. d,
1H, 3J(1H-1H)=7.8 Hz, phenyl-CH), 7.66 (br. d, 1H, 3J(1H-1H)=10.1 Hz,
phenyl-CH), 7.44 (dt, 1H, 3J(1H-1H)=8.2, 6.0 Hz, phenyl-CH), 7.22 (td,
1H, 3J(1H-1H)=8.4 and 4J(1H-1H)=1.8 Hz, phenyl CH), 6.68 (s, 1H,
methine CH), 4.95 (br. s, 2H, Cp-CH), 4.52 (br. s, 2H, Cp-CH), 4.11 (s,
5H, Cp-C5H5);
13C{1H} NMR (125 MHz, (CD3)2CO, δ): 196.0 (Q, CO),
178.37 (Q, CO), 163.9 (d, Q, CF, 1J(13C-19F)=243.9 Hz), 138.6 (d, Q
phenyl-C, 3J(13C-19F)=7.8 Hz), 131.5 (d, phenyl-CH, 3J(13C-19F)=
8.3 Hz), 123.6 (d, phenyl-CH, 4J(13C-19F)=2.1 Hz), 119.4 (d„ phenyl-
CH, 2J(13C-19F)=21.8 Hz,), 114.2 (d„ phenyl-CH, 2J(13C-19F)=23.9 Hz),
95.1 (methine CH), 79.0 (Q, Cp), 73.5 (Cp-CH), 71.2 (Cp-C5H5), 69.9
(Cp-CH); Analysis Calculatedfor C19H15FFeO2: C 65.17, H 4.32%,
Found C 65.10, H 4.30%; HRMS [ES+]: 349.032 [M  H+]
[C19H15ClFeO2] (3): The product was purified by column chromatog-
raphy, eluting with 90 :10 v/v hexane/ethyl acetate to give a red
solid. Yield: 1.89 g, 72%; 1H NMR (500 MHz, (CD3)2CO, δ): 7.92 (t, 1H,
4J(1H-1H)=1.8 Hz, phenyl-CH), 7.88 (dt, 1H, 3J(1H-1H)=7.8 and 4J
(1H-1H)=1.3 Hz, phenyl-CH), 7.48 (dq, 1H, 3J(1H-1H)=7.8 and 4J
(1H-1H)=1.0 Hz, phenyl-CH), 7.42 (t, 1H, 3J(1H-1H)=7.8 Hz, phenyl-
CH), 6.70 (s, 1H, methane CH), 4.95 (t, 2H, 3J(1H-1H)=2.0 Hz, Cp-CH),
4.52 (t, 2H, 3J(1H-1H)=2.0 Hz, Cp-CH), 4.12 (s, 5H, Cp-C5H5);
13C{1H}
NMR (125 MHz, (CD3)2CO, δ): 196.0 (Q, CO), 178.3 (Q, CO), 138.2 (Q,
phenyl-C), 135.2 (Q, C–Cl), 132.4 (phenyl-CH), 131.3 (phenyl-CH),
127.4 (phenyl-CH), 126.1 (phenyl-CH), 95.1 (methine CH), 79.0 (Q,
Cp), 73.5 (Cp-CH), 71.2 (Cp-C5H5), 69.9 (Cp-CH); Analysis Calculated
for C19H15ClFeO2: C 62.25, H 4.12%, Found: C 62.18, H 4.13%; HRMS
[ES+]: 366.010 [MH+]
[C19H15BrFeO2] (4): The product was purified by column chromatog-
raphy, eluting with 90 :10 v/v hexane/ethyl acetate to give a red
solid. Yield: 2.32 g, 78%; 1H NMR (500 MHz, (CD3)2CO, δ): 8.07 (t, 1H,
4J(1H-1H)=1.6 Hz, phenyl-CH), 7.93 (dt, 1H, 3J(1H-1H)=7.8 and 4J
(1H-1H)=1.1 Hz, phenyl-CH), 7.62 (dt, 1H, 3J(1H-1H)=8.0 and 4J
(1H-1H)=0.8 Hz, phenyl-CH), 7.36 (t, 1H, 3J(1H-1H)=7.9 Hz, phenyl-
CH), 6.69 (s, 1H, methine CH), 4.94 (t, 2H, 3J(1H-1H)=1.8 Hz, Cp-CH),
4.52 (t, 2H, 3J(1H-1H)=1.8 Hz, Cp-CH), 4.11 (s, 5H, Cp-C5H5);
13C{1H}
NMR (125 MHz, (CD3)2CO, δ): 196.0 (Q, CO), 178.3 (Q, CO), 138.4 (Q,
phenyl-C), 135.4 (phenyl-CH), 131.5 (phenyl-CH), 130.3 (phenyl-CH),
126.5 (phenyl-CH), 123.3 (Q, C-Br), 95.1 (methine CH), 79.0 (Q, Cp),
73.5 (Cp-CH), 71.2 (Cp-C5H5), 69.9 (Cp-CH); Analysis Calculated for
C19H15BrFeO: C 55.52, H 3.68%, Found: C 55.54, H 3.77%; HRMS [ES
+
]: 409.960 [MH+]
[C19H15FFeO2] (5): The product was purified by column chromatog-
raphy, eluting with 80 :20 v/v hexane/ethyl acetate to give a red
solid. Yield: 1.59 g, 63%; 1H NMR (500 MHz, (CD3)2CO, δ): 8.10 (m,
2H, phenyl-CH), 7.29 (t, 2H, 3J(1H-1H)=8.7 Hz, phenyl-CH), 6.59 (s,
1H, methine CH), 5.00 (t, 2H, 3J(1H-1H)=1.8 Hz, Cp-CH), 4.66 (t, 2H, 3J
(1H-1H)=1.8 Hz, Cp-CH), 4.26 (s, 5H, Cp-C5H5);
13C{1H} (125 MHz,
(CD3)2CO, δ): 195.0 (Q, CO), 179.7 (Q, CO), 165.8 (d, Q, C-F,
1J(13C-19F)
=250.2 Hz), 132.6 (d, Q, phenyl-C, 4J(13C-19F)=2.1 Hz), 130.3 (d,
phenyl-CH, 3J(13C-19F)=9.3 Hz), 116.4 (d, phenyl-CH, 2J(13C-19F)=
21.8 Hz), 94.4 (methine CH), 73.5 (Q, Cp), 73.2 (Cp-CH), 71.1 (Cp-
C5H5), 70.8 (Cp-CH), 70.6 (Cp-CH), 69.8 (Cp-CH); Analysis Calculated
for C19H15FFeO2: C 65.17, H 4.32%, Found: C 65.00, H 4.40%; HRMS
[ES+]: 349.330 [M  H+]
[C19H15ClFeO2] (6): The product was purified by column chromatog-
raphy, eluting with 83 :17 v/v hexane/ethyl acetate to give a red
solid. Yield: 1.65 g, 63%; 1H NMR (500 MHz, (CD3)2CO, δ): 7.95 (d, 2H,
3J(1H-1H)=8.7 Hz, phenyl-CH), 7.41 (d, 2H, 3J(1H-1H)=8.7 Hz, phenyl-
CH), 6.36 (d, 1H, 3J(1H-1H)=5.5 Hz, methine CH), 4.92 (br. t, 2H, 3J
(1H-1H)=1.7 Hz, Cp-CH), 4.51 (br. t, 2H, 3J(1H-1H)=1.7 Hz, Cp-CH),
4.11 (s, 5H, Cp-C5H5);
13C{1H} NMR (125 MHz, (CD3)2CO, δ): 195.7 (Q,
CO), 178.9 (Q, CO), 134.9 (Q, phenyl-C), 131.4 (Q, C-Cl), 129.7
(phenyl-CH), 129.3 (phenyl-CH), 94.8 (methine CH), 79.1 (Q, Cp), 73.4
(Cp-CH), 71.2 (Cp-C5H5), 69.8 (Cp-CH); Analysis Calculated for
C19H15ClFeO2: C 62.25, H 4.12, Cl 9.67%, Found: C 62.30, H 4.10, Cl
9.50%; HRMS [ES+]: 366.011 [MH+]
[C19H15BrFeO2] (7): The product was purified by column chromatog-
raphy, eluting with 90 :10 v/v hexane/ethyl acetate to give a red
solid. Yield: 2.76 g, 93%; 1H NMR (500 MHz, (CD3)2CO, δ): 7.87 (d, 2H,
3J(1H-1H)=8.0 Hz, phenyl-CH), 7.58 (d, 2H, 3J(1H-1H)=7.1 Hz, phenyl-
CH), 6.66 (s, 1H, methine CH), 4.92 (br. s, 2H, Cp-CH), 4.51 (br. s, 2H,
Cp-CH), 4.11 (s, 5H, Cp-C5H5);
13C{1H} NMR (125 MHz, CDCl3, δ): 194.3
(Q, CO), 178.5 (Q, CO), 134.2 (Q, phenyl-C), 131.9 (phenyl-CH), 128.2
(phenyl-CH), 126.5 (Q, C-Br), 93.6 (methine CH), 78.0 (Q, Cp), 72.4
(Cp-CH), 70.4 (Cp-C5H5), 68.8 (Cp-CH); Analysis Calculated for
C19H15BrFeO2 (+0.75 DCM): C 49.96, H 3.50%, Found: C 50.00, H
3.20%; HRMS [ES+]: 409.960 [MH+]
Synthesis of complexes 8–14: 1-Ferrocenylbutane-1,3-dione (com-
pound 1, 1 eq.) was dissolved in ethanol (20 mL) followed by the
addition of a functionalized aniline (2 eq.) and concentrated
hydrochloric acid (2 mL). The reaction was stirred at room temper-
ature for 3 days. The solution was filtered and the solvent removed
in vacuo.
[C20H19FeNO] (8): The crude solid was dissolved in ethyl acetate/
hexane (1 :4) and filtered through a silica plug. The solvent was
removed, leaving a red solid. Red crystals were obtained upon slow
evaporation from acetone. Yield: 0.86 g, 68%; 1H NMR (300 MHz,
(CD3)2CO, δ): 12.86 (s, 1H, NH), 7.50–7.34 (m, 2H, phenyl-CH), 7.31–
7.14 (m, 3H, phenyl-CH), 5.65 (s, 1H, methine CH), 4.86–4.75 (m, 2H,
m, Cp-CH), 4.47–4.37 (m, 2H, Cp-CH), 4.17 (s, 5H, Cp-C5H5), 2.16 (s,
3H, CH3);
13C{1H} NMR (101 MHz, (CD3)2CO, δ): 193.00 (Q, CO), 159.15
(Q, phenyl-C), 139.32 (Q, CNH), 129.22 (phenyl-CH), 125.18 (phenyl-
CH), 124.33 (phenyl-CH), 95.68 (methine CH), 82.45 (Q, Cp), 71.05
(Cp-CH), 69.94 (Cp-C5H5), 68.60 (Cp-CH), 20.58 (CH3). HRMS [ES
+]:
346.0915 [M  H+] (calculated 346.0889)
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[C20H18FFeNO] (9): The crude solid was dissolved in ethyl acetate/
hexane (3 :7) and filtered through a silica plug. The solvent was
removed, and the crude product was dissolved in an ethanol/ether
mixture, and cooled to   20 °C overnight, yielding red crystals. Yield:
0.49 g, 40%; 1H NMR (300 MHz, (CD3)2CO, δ): 12.89 (s, 1H, NH),
7.42(m, 1H, phenyl-CH), 7.07 (m, 2H, phenyl-CH) 6.94 (m, 1H,
phenyl-CH), 5.69 (s, 1H, methine CH), 4.85–4.77 (m, 2H, Cp-CH),
4.49–4.40 (m, 2 H, Cp-CH), 4.17 (s, 5H, Cp-C5H5), 2.22 (s, 3H, CH3);
13C
{1H} NMR (101 MHz, (CD3)2CO, δ): 192.81 (Q, CO), 157.80 (Q, phenyl-
C), 142.51 (Q, CNH), 139.24 (phenyl-CH), 130.72 (phenyl-CH), 119.08
(Q, C-Fl), 110.92 (phenyl-CH), 110.10 (phenyl-CH), 96.56 (methine
CH), 83.67 (Q, Cp), 70.87 (Cp-CH), 70.27 (Cp-C5H5), 69.50 (Cp-CH),
19.56 (CH3); HRMS [ES
+]: 364.0845 [M  H+]
[C20H18ClFeNO] (10): The crude solid was dissolved in ethyl acetate/
hexane (1 :4) and filtered through a silica plug. The solvent was
removed, leaving a red solid. Red crystals were obtained upon slow
evaporation from acetone. Yield: 0.82 g, 58%; 1H NMR (300 MHz,
(CD3)2CO, δ): 12.87 (s, 1H, NH), 7.46–7.34 (m, 1H, phenyl-CH), 7.29 (t,
1H, 4J(1H-1H)=2.0, phenyl-CH), 7.20 (dd, 2H, 3J(1H-1H)=7.9 and 4J
(1H-1H)=1.9, phenyl-CH), 5.69 (s, 1H, methine CH), 4.81 (s, 2H, Cp-
CH), 4.43 (s, 2H, Cp-CH), 4.17 (s, 5H, Cp-C5H5), 2.21 (s, 3H, CH3);
13C
{1H} NMR (100 MHz, (CD3)2CO, δ): 192.85 (Q, CO), 157.80 (Q, phenyl-
C), 141.17 (Q, CNH), 134.21 (phenyl-CH), 130.58 (phenyl-CH), 124.23
(phenyl-CH), 123.02 (phenyl-CH), 121.78 phenyl-CH), 96.61 (methine
CH), 82.38 (Q, Cp), 70.90 (Cp-CH), 69.63 (Cp-C5H5), 68.51 (Cp-CH),
19.51 (CH3); Analysis Calculated for C20H18ClFeNO: C 63.27 H 4.78 N
3.69 Cl 9.34%; Found: C 62.90 H 4.80 N 3.50 Cl 9.10%; HRMS [ES+]:
380.0507 [M+H]+
[C20H18BrFeNO] (11): The crude solid was dissolved in ethyl acetate/
hexane (1 :4) and filtered through a silica plug. The solvent was
removed, leaving a red solid. Red crystals were obtained upon slow
evaporation from acetone. Yield: 0.62 g, 39%; 1H NMR (300 MHz,
(CD3)2CO, δ): 12.86 (s, 1H, NH), 7.44 (br. t, 1H, phenyl-CH), 7.39–7.18
(m, 2H, phenyl-CH), 7.29–7.21 (m, 1H, phenyl-CH), 5.69 (s, 1H,
methine CH), 4.85–4.77 (m, 2H, Cp-CH), 4.48–4.40 (m, 2H, Cp-CH),
4.17 (s, 5H, Cp-C5H5), 2.20 (s, 3H, CH3);
13C{1H} NMR (100 MHz,
(CD3)2CO, δ) 192.83 (Q, CO), 157.76 (Q, phenyl-C), 157.37 (Q, CNH),
141.31 (phenyl-CH), 130.83 (phenyl-CH), 127.21 (phenyl-CH), 125.94
(phenyl-CH), 122.22 (phenyl-CH), 96.62 (methine CH), 82.39 (Cp-CH),
70.89 (Cp-CH), 70.06 (Cp-C5H5), 69.63 (Cp-CH), 19.48 (CH3); Analysis
Calculated for C20H18BrFeNO: C 56.64 H 4.28 N 3.30%; Found: C
56.10 H 4.30 N 3.00%; HRMS [ES+]: 425.9996 [M+H]+
[C20H18FFeNO] (12): After addition of HCl, the reaction was heated
to 80 °C and stirred overnight. The solution was filtered and the
remaining solid washed with toluene and petroleum ether. The
solvent was removed, leaving a red-brown oil, before being purified
by column chromatography, eluting with 80 :20 dichloromethane/
petroleum ether to give an orange solid. Yield: 0.49 g, 34%; 1H
(300 MHz, (CD3)2CO, δ) : 12.73 (s, 1H, ΝΗ), 7.29 (dd, 2H,
3J(1H-1H)=
9.0 and 4J(1H-1H)=4.9, phenyl-CH), 7.23 (br. tt, 2H, phenyl-CH), 5.65
(s, 1H, methine CH), 4.79 (t, 2H, 4J(1H-1H)=1.9, Cp-CH), 4.41 (t, 2H, 4J
(1H-1H)=1.9, Cp-CH), 4.16 (s, 5H, Cp-C5H5), 2.10 (s, 3H, CH3);
13C{1H}
NMR (500 MHz, (CD3)2CO, δ) 193.3 (Q, CO), 162.0 (Q, C-Cl), 159.8
(phenyl-CH), 136.6 (Q, CNH), 126.9 (phenyl-CH), 116.6 (phenyl-CH),
96.3 (methine CH), 83.6 (Cp-CH), 72.8 (Cp-CH), 70.9 (Cp-C5H5), 69.4
(Cp-CH), 20.1 (CH3); Analysis Calculated for C20H18FFeNO: C 67.65, H
5.00, N 3.86%; Found: C 64.90, H 5.10, N 5.70%; HRMS [ES+]:
364.0798 [M+H]+
[C20H18ClFeNO] (13): The reaction mixture was stirred at room
temperature overnight. TLC showed the presence of 1-ferrocenyl-
butane-1,3-dione but no aniline. A further 0.93 g (7.4 mmol) of 4-
chloroaniline was added and the reaction mixture stirred for
another 2 days. The solvent was removed in vacuo and the resulting
solid purified by column chromatography, eluting with ethyl
acetate/hexane (1 :9). The resulting solid was recrystallized from hot
ethanol, giving red crystals. Yield: 0.69 g, 49%; 1H (300 MHz,
(CD3)2CO, δ) : 12.87 (s, 1H, NH), 7.45 (d, 2H,
3J(1H-1H)=8.8, phenyl-
CH), 7.30 (d, 2H, 3J(1H-1H)=8.8, phenyl-CH), 5.71 (s, 1H, methine CH),
4.90–4.80 (m, 2H, Cp-CH), 4.52–4.42 (m, 2H, Cp-CH), 4.20 (s, 5H, Cp-
C5H5), 2.21 (s, 3H, CH3);
13C{1H} NMR (100 MHz, (CD3)2CO, δ): 193.54
(Q, CO), 159.00 (Q, CNH), 139.42 (Q, phenyl-C), 130.04 (phenyl-CH),
125.94 (phenyl-CH), 97.09 (methine CH), 83.41 (Q, Cp), 71.70 (Cp-
CH), 70.50 (Cp-C5H5), 69.36 (Cp-CH), 20.30 (CH3). Analysis Calculated
for C20H18ClFeNO: C 63.27, H 4.78, N 3.69, Cl 9.34%, Found: C 63.00,
H 4.90, N 3.40, Cl 9.25%. HRMS [ES+]: 380.0510 [M  H+]
[C20H18ClFeNO] (14): The crude solid was dissolved in ethyl acetate/
hexane (1 :4), and filtered through a silica plug. The solvent was
removed and the red solid recrystallized from hot ethanol yielding
red crystals. Yield: 0.72 g, 46%; 1H (300 MHz, (CD3)2CO, δ): 12.83 (s,
1H, NH), 7.55 ('d, 2H, 3J(1H-1H)=8.8, phenyl-CH), 7.21 (d, 2H, 3J
(1H-1H)=8.8, phenyl-CH), 5.68 (s, 1H, methine CH), 4.84–4.76 (m, 2H,
Cp-CH), 4.47–4.39 (m, 2H, Cp-CH), 4.17 (s, 5H, Cp-C5H5), 2.18 (s, 3H,
CH3);
13C{1H} NMR (300 MHz, [D6]DMSO, δ): 192.72 (Q, CO), 158.51
(Q, CNH), 138.80 (Q, phenyl-C), 132.50 (phenyl-CH), 125.65 (phenyl-
CH), 117.16 (phenyl-CH), 96.73 (methine CH), 82.52 (Q, Cp), 71.39
(Cp-CH), 70.02 (Cp-C5H5), 68.82 (Cp-CH), 20.41 (CH3); Analysis
Calculated for C20H18ClFeNO: C 56.64, H 4.28, N 3.30, Br 18.84%,
Found: C 56.50, H 4.35, N 3.10, Br 18.70%. HRMS [ES+]: 425.999
[M  H+]
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COMMUNICATIONS
The cell seekers: We report the
synthesis of new β-diketonate and β-
ketoiminate ligands that have been
functionalized with a ferrocenyl
moiety. The ferrocenyl β-diketonate
compounds have high IC50 values
and are more selectivity towards
cancerous cells, in particular human
breast carcinomas. Some compounds
are up to 9 times more cytotoxic and
selective when compared to carbo-
platin.
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